Entering text into the input field will update the search result below
Create free account
Search for Symbols, analysts, keywords
Log in
ALDX
Aldeyra Therapeutics, Inc.
Latest News
Follow
$3.08
0.16 (+5.48%)
4:00 PM 03/27/24
NASDAQ |
$USD |
Pre-Market:
$3.10
+0.02 (+0.64%)
8:49 AM
Summary
Ratings
Financials
Earnings
Dividends
Valuation
Growth
Profitability
Momentum
Peers
Options
Charting
All
Analysis
Comments
News
Transcripts
SEC Filings
Press Releases
Related Analysis
ALDX News
Show Full Stories
Show Full Stories
This feature available only for pro users
Type:
All Types
Date Range:
Select Date
Aldeyra Therapeutics files for $200M mixed securities shelf
Abbvie extends option agreement with Aldeyra for dry eye candidate
Aldeyra stock jumps 8% on dermatitis drug updates
FDA says more data needed to approve Aldeyra dry eye drug (update)
AbbVie enters option deal for Aldeyra dry eye disease drug
Aldeyra Therapeutics 10% owner disposes stake worth $4.45M
Aldeyra says FDA may not approve dry eye drug, stock plunges 69% (update)
Acumen, BridgeBio, Arcus among BTIG's top healthcare picks for 2H 2023
Aldeyra reports positive mid-stage results for retinitis pigmentosa candidate
Aldeyra gains on positive mid-stage data for cough therapy
Aldeyra Therapeutics to join Russell 2000 and Russell 3000 indexes
Aldeyra crashes 21% as FDA rejects eye cancer therapy
Aldeyra up 7% on late-stage data for conjunctivitis candidate
Aldeyra Therapeutics GAAP EPS of -$0.27 beats by $0.02
Aldeyra Therapeutics gains amid takeover speculation
Aldeyra Therapeutics GAAP EPS of -$1.06 beats by $0.10
Notable earnings before Thursday's open
FDA accepts for priority review Aldeyra's ADX-2191 application in retinal cancer
Aldeyra gains on safety data for dry eye disease candidate
Aldeyra stock rises as dry eye disease drug gets FDA review
Aldeyra files for FDA approval of ADX‑2191 for rare eye cancer
Aldeyra Therapeutics seeks FDA approval of its treatment for dry eye disease symptoms
Aldeyra Therapeutics GAAP EPS of -$0.25 beats by $0.10
Aldeyra Therapeutics Q3 2022 Earnings Preview
Aldeyra stock rises as eye disorder drug ADX-2191 meets main goal in part 1 of phase 3 trial
Aldeyra Therapeutics on track to submit new drug application for dry eye disease treatment
Aldeyra Therapeutics stock rises 13% on Q2 beat with eyes on approval path for reproxalap
Aldeyra Therapeutics GAAP EPS of -$0.30 beats by $0.02
Aldeyra says trial for dry eye disease candidate reached key goals
Aldeyra stock soars as dry eye disease drug meets main goal in late stage study
Aldeyra says post-hoc analysis shows its eye therapy reduced ocular redness
Aldeyra Therapeutics GAAP EPS of -$0.29 beats by $0.04
Aldeyra Therapeutics Q1 2022 Earnings Preview
Aldeyra Therapeutics CFO steps down, interim CFO appointed
Mid-stage trials show proof of concept for Aldeyra immune-mediated disease candidate
Aldeyra Therapeutics GAAP EPS of -$1.07 beats by $0.02
Aldeyra Therapeutics starts phase 2 trial of ADX-2191 to treat rare eye disorders
Aldeyra reports positive top-line data from Phase 2 reproxalap study in dry eye disease
Aldeyra Therapeutics completes enrollment in part 1 of phase 3 study of eye disorder drug
Aldeyra defended at Citi despite setback to dry eye disease study for reproxalap
1
2
3
4
5
Next
People Also Follow
Similar to ALDX
ETFs Holding ALDX
To ensure this doesn’t happen in the future, please enable Javascript and cookies in your browser.
Is this happening to you frequently? Please
report it on our feedback forum.
If you have an ad-blocker enabled you may be blocked from proceeding. Please disable your ad-blocker and refresh.